AUS
NZ
UK
CA
USA
IND
On July 27, 2026, Codexis, Inc. successfully closed a public stock offering, issuing 16.7 million shares at $1.50 per share. The biotechnology firm netted approximately $23.1 million after deducting underwriting fees and expenses. Piper Sandler & Co. and Cantor Fitzgerald & Co. underwrote the offering, retaining a 30-day option to purchase an additional 2.5 million shares.
Key Points
- NASDAQ: CDXS
- Codexis completed a public offering of 16.7 million common shares on July 27, 2026
- Shares priced at $1.50 each, yielding net proceeds of about $23.1 million after fees
- Underwriters have a 30-day option to buy up to 2.5 million additional shares at the same price
- Company executives and directors are subject to a 90-day lock-up restricting share sales without underwriter approval
Details of Offering Structure and Pricing
Codexis entered into an underwriting agreement on July 23, 2026, with Piper Sandler & Co. and Cantor Fitzgerald & Co. acting as lead representatives. The company agreed to sell 16.7 million common shares at a fixed price of $1.50 per share, establishing the valuation for this equity capital raise.
The underwriters were granted a 30-day over-allotment option, commonly known as a "green shoe," allowing them to purchase up to 2.5 million additional shares from the company at the same price. This option provides flexibility to stabilize the stock price and meet investor demand post-offering.
Net Proceeds and Use of Capital
Following the offering’s close on July 27, 2026, Codexis received net proceeds of approximately $23.1 million after underwriting discounts, commissions, and estimated expenses. These funds enhance the company’s liquidity to support operations, research and development, and other corporate initiatives.
Investors should watch for future disclosures in quarterly and annual filings to understand management’s plans for deploying these proceeds and the potential impact on Codexis’s financial health and operational capabilities.
Lock-Up Agreement and Trading Restrictions
Codexis and its directors and executive officers agreed to a 90-day lock-up period starting July 23, 2026, restricting sales or transfers of shares without prior written consent from the underwriting representatives. This measure aims to prevent significant insider selling that could disrupt the stock price immediately after the offering.
Exceptions to this lock-up, detailed in the prospectus supplement filed with the SEC, typically include pre-established Rule 10b5-1 trading plans, sales to meet tax obligations, or other agreed-upon circumstances.
Underwriting Syndicate and Legal Framework
The offering was managed jointly by Piper Sandler & Co. and Cantor Fitzgerald & Co., who organized the sale and resale of shares to public investors. Codexis agreed to indemnify the underwriters against liabilities under the Securities Act of 1933, a standard provision protecting underwriters from losses due to misstatements or omissions.
Regulatory Compliance and Registration
This offering was conducted under Codexis’s shelf registration statement on Form S-3 (Registration No. 333-279082), previously declared effective by the SEC. The shelf registration facilitates efficient capital raises without filing a new registration for each offering.
Detailed information about the offering and company risks is provided in the prospectus supplement and base prospectus filed with the SEC, ensuring investors have comprehensive disclosure.
Legal Opinion and Documentation
Latham & Watkins LLP issued a legal opinion confirming the valid issuance of the shares, filed as Exhibit 5.1. The underwriting agreement dated July 23, 2026, was also filed as an exhibit, outlining the full terms, conditions, and indemnification provisions of the offering.
Offering Timeline and Disclosure
The underwriting agreement was executed on July 23, 2026, with the offering closing four business days later on July 27, 2026. The contemporaneous filing of this disclosure ensures transparency for investors and market participants regarding the capital raise.
Impact on Capital Structure and Dilution
The issuance of 16.7 million shares significantly increases Codexis’s outstanding common stock, diluting existing shareholders’ ownership unless they participated in the offering. The total shares outstanding prior to the offering were not disclosed.
If the underwriters exercise their full 2.5 million share over-allotment option within 30 days, the total shares issued could rise to 19.2 million, further affecting share count and per-share metrics.
Investor Considerations Moving Forward
Investors should monitor Codexis’s upcoming quarterly and annual reports for updates on the use of the $23.1 million net proceeds, including allocations toward R&D, working capital, acquisitions, or debt repayment. Management’s capital allocation strategy may also be discussed in earnings calls and investor presentations.
The potential exercise of the underwriters’ over-allotment option and the expiration of the 90-day lock-up period in late October 2026 are additional factors investors should watch for insights into insider selling and share count changes.
